Ποια είναι η τιμή για Harpoon Therapeutics, Inc. (HARP)

Η τιμή για Harpoon Therapeutics, Inc. (HARP) είναι $23.01

Ποια είναι η κεφαλαιοποίηση αγοράς για Harpoon Therapeutics, Inc. (HARP)

Η κεφαλαιοποίηση αγοράς για Harpoon Therapeutics, Inc. (HARP) είναι $74.80M

Harpoon Therapeutics, Inc. (HARP) Τιμή και Κεφαλαιοποίηση Αγοράς

Harpoon Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to immunotherapy, focused on engineering a novel class of T cell activators. These therapies are designed to leverage the body's own immune system to fight cancer and other diseases in patients across the United States. The company's innovative Tri-specific T cell activating construct (TriTAC) platform forms the basis of its development pipeline. This includes HPN328, currently undergoing Phase I/II clinical trials for small cell lung cancer and tumors that express Delta-like canonical Notch ligand 3; HPN217, also in Phase I/II trials for the treatment of multiple myeloma; and HPN536, which is in Phase I/IIa clinical evaluation for ovarian and pancreatic cancers, alongside other mesothelin-expressing tumors. Furthermore, Harpoon has a preclinical asset, HPN601, aimed at various solid tumor indications. The company has also established a discovery collaboration and licensing agreement with AbbVie Biotechnology Ltd. to develop and market products combining its unique TriTAC technology with soluble T cell receptors. Founded in 2015, Harpoon Therapeutics, Inc. is headquartered in South San Francisco, California.

Η τιμή για HARP	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$1,603,220 $74.80M	NVDA	$5.211T	+6,967,392.92%
$1,398,756 $74.80M	AAPL	$4.547T	+6,078,805.78%
$1,280,540 $74.80M	GOOG	$4.162T	+5,565,044.67%
$1,105,282 $74.80M	MSFT	$3.593T	+4,803,387.23%
$859,191 $74.80M	AMZN	$2.793T	+3,733,888.73%

Η τιμή για HARP

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$1,603,220 $74.80M